Citation:Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, et al 2006

From Cancer Guidelines Wiki

Citation


Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006 Dec;32(8):583-7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16919884.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, et al 2006What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, et al 2006 2What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Bria_E,_Cuppone_F,_Ciccarese_M,_Nisticò_C,_Facciolo_F,_Milella_M,_et_al_2006&oldid=21649"